This paper describes a bipartite antisense oligonucleotide (5D‑ASO) design that appends a short 5′ splice site decoy tail to improve exon skipping, demonstrating robust efficacy for DMD exon 51 in cells, mice, and cynomolgus monkeys with a favorable safety profile.
0:00Welcome to Base by Base, the paper cast that brings genomics to you, wherever you are. Thanks for listening, and don't forget to follow and rate us in your podcast app. Imagine you were reading a critical instruction manual.
0:12Oh, right, like something you absolutely need to get right. Exactly. Let's say it is the manual on how to build a vital engine component for a jet you are, you know, currently flying. You're reading along, line by line, but suddenly you hit a page that is just completely garbled.
0:27Like a printing error. Yeah, the text is a mess. The diagrams are overlapping. And because of this one ruined page, the rest of the book is completely impossible to read. The instructions are just broken.
0:36That sounds stressful. It is. But now, what if you could just slap a sticky note over that specific garbled page? A note telling the reader to simply skip it, allowing the rest of the manual to flow and make enough sense to, well, keep the engine running.
0:51So if we translate that manual into human biology, the book is your DNA, and that garbled page is a genetic mutation, and the sticky note is a therapeutic approach. It's designed to bypass the error so the cell can still produce a functional, albeit, you know, slightly shorter protein.
1:09That is exactly what scientists do to treat severe genetic diseases. What happens when that sticky note just isn't sticky enough. Or, what if the body's cellular machinery simply ignores the note entirely and tries to read the garbled page anyway?
1:24Exactly. How can we force the cell to pay attention without causing total chaos? That is the core puzzle we are diving into today. It's a puzzle that has really frustrated the field of RNA therapeutics for years.
1:37I mean, the conceptual idea of the sticky note approach is incredibly sound on paper. Yeah, it makes perfect sense. But it is constantly met with the harsh reality of biological delivery and, well, cellular resistance.
1:49Today we celebrate the work of an international and multi-institutional team who have advanced our understanding of RNA targeted therapeutics and muscular dystrophy. It's a massive collaboration. It really is.
2:01We are pulling from a 2026 paper published in PNAS, looking at a breakthrough involving researchers from managing antisense biofarm, Nanjing Normal University, Cold Spring Harbor Laboratory, and Guanzu a Secura Pharmaceuticals.
2:16And our mission for this deep dive is to understand not just what they discovered, but how they completely redesigned our approach to genetic editing. Right, but to really grasp the weight of their methodology, we need to establish the clinical problem they're addressing.
2:30Yeah, we're talking about Duchenne, muscular dystrophy, or DMD. Which is devastating. It is a severe genetic disorder. It is caused by mutations, often large deletions of genetic code, actually, in the DMD gene, and that gene is responsible for producing a protein called dystrophen.
2:47Dystrophin. So that is essentially the shock absorber for our muscle fibers, right? That's a great way to put it. It anchors the internal cytoskeleton of a muscle cell to the extracellular matrix. It basically protects the fibers from the mechanical stress of contracting and relaxing.
3:01So without that shock absorber. Without it, every single time a muscle contracts, the cell membrane sustain tiny tears. So the muscle cells progressively accumulate damage, they become inflamed and eventually die.
3:15And they get replaced by fat and scar tissue, right? Exactly. In DMD, these genetic mutations disrupt the reading frame. Returning to your manual analogy, the garbled page doesn't just confuse the reader.
3:27It shifts all the subsequent text out of alignment. Yes. The cellular machinery reads it, produces nonsense, and prematurely stops building the distruff and protein altogether. And the result is severe progressive muffled degeneration, affecting skeletal muscles, and critically, the heart.
3:46Yeah, the cardiac implications are usually the most fatal part. Okay, let's unpack this. If you are listening to this and keeping up with genetic medicine, you might be thinking, well, we aren't starting from 0 here.
3:55Right, we're not. We already have FDA approved drugs that act as our genetic sticky notes. There's a well-known one called a Teplarsen. Yeah, a Tepler sin is an anti-sense oligonucleotide, or ASO. It's a short, synthetic string of nucleic acids, and it's designed to bind to a specific region of the pre-MRNA specifically, a section called Exon 51.
4:17Exxon 51. Got it. By binding there, it physically masks the exon from the cell's splicing machinery. The spliceosome, which acts like a molecular editor, sees the ASO, skips over exon 51 entirely and splices the surrounding pieces together.
4:33Restoring the reading frame. Exactly, allowing the cell to produce a partially functional truncated dystrophin protein. Wait, if a Teplerson already acts as a sticky note and successfully skips the faulty Exxon.
4:44I'm confused why this new paper even exists, is the human body just washing the sticky note away? The limitation lies in pharmacokinetics, how the drug moves through and behaves in the body. The current generation of ASOs basically lack the necessary potency.
4:57A Teplerson and similar conditionally approved ASOs have limited clinical efficacy because they struggle to achieve robust therapeutic outcomes and extra hepatic tissues. Extrapatic meaning outside the liver.
5:07Because the liver acts as the body's filter, it tends to absorb the vast majority of any drug you in check, doesn't it? Yes, exactly. The liver acts like a sponge for these therapeutics. Getting enough of the drug past the liver and specifically into skeletal muscle is incredibly difficult.
5:24can imagine. And getting it into cardiac muscle is a massive hurdle. As a result, you have to administer incredibly high, repeated doses just to get a marginal clinical benefit. So the sticky note works in a test tube, but in the actual human body, the muscle cells are fortified like castles.
5:42And even if a few sticky notes get inside, the cell's editor is just reading right through them. Yeah, the cell's natural splicing signals are just very strong. The ASO is essentially competing with the cell's own highly efficient machinery to overcome this.
5:56The researchers in this study didn't just try to force more drug into the cells. They completely redesigned the architecture of the sticky note itself. Oh wow. Yeah, they developed a breakthrough technology they call the 5 D-A-S-O, which stands for 5 foot splice site decoy AS-O.
6:12Hold on, you just lost me. You won SNRNA. Five foot splice sites. Let's take a step back. What exactly is a U1 scout doing in a normal healthy cell? Okay, fair enough. In a healthy cell, your DNA is transcribed into a rough draft of RNA called pre-MRNA.
6:29This rough draft has alternating sections, Exxons, which are the important instructions and introns, which are filler sequences that need to be cut out. The machinery that cuts out the introns and pastes the Exxons together is called the spliceosome.
6:42Okay, so the splice of some is the factory machine doing the actual cutting and pasting. Exactly. And the splic system needs to know exactly where to cut. That is where U1 comes in. U1 is a small nuclear ribonuclear protein.
6:54It's mouthful. Yeah, it's a complex of RNA and proteins. Just think of it as the scout for the splice system. It physically scans the rough draft of RNA, hunting for a specific sequence of letters called the 5 Foit site.
7:06That site marks the boundary of an Exxon. Oh I see. When you one finds that site and binds to it, it flags the area. It's essentially shouting to the rest of the spice of some, hey, cut here. So the traditional drug, a Templarsen, just lays flat over that boundary to hide it from the U1 scout.
7:21But what does this new 5D ASO do differently? A 5D ASO is a two-part molecule. The main body of the molecule is the traditional anti-sense portion. It targets and binds to the specific exon we want to skip, just like the old drugs.
7:36Okay, so that part is the same. But the innovation is the addition of a tiny tail. It's a carefully designed sequence of just 8 nucleotides dangling off the end. So instead of just laying a flat, sticky note over the genetic typo, we're attaching a little tail to it, like a lure on a fishing line to distract the cell's editing machinery.
7:54That is exactly it. That physical distraction is the core mechanism. The researchers optimize those 8 nucleotides to perfectly mimic a 5 foot splice site. Because it's a perfect chemical match, it base pairs with the free end of the U1 scout.
8:08So when the 5D ASO enters the nucleus and binds to the Exxon we want to skip, that dangling tail acts as a powerful decoy. It snags the U1 complexes right out of the local environment. It sequesters them.
8:20The local splicing machinery gets completely misdirected away from the actual boundaries of the Exxon. The Exxon is repressed and the skipping effect is drastically enhanced. Wait, I need to clarify something.
8:32When we talk about these drugs, we often hear terms like MOE and PMO. Are those just chemical armors we put on the RNA, so the body doesn't chew it up? Yeah, they function as molecular armor. And so does adding this decoy tail complicate that armor.
8:45Not at all. Naturally occurring RNA is incredibly fragile. If you inject raw RNA into the bloodstream, enzymes called nucleuses will shred it in minutes, so scientists use modified chemical backbones like MOE or PMO or OMA modifications.
8:59Right, to make the drug invisible to the nucleuses. Exactly. What is vital about the 5D ASO design is that the decoy mechanism relies purely on basic RNA base pairing. It doesn't require recruiting bulky secondary proteins to work.
9:14Therefore, the researchers found that this 8 nuclear tide tail works seamlessly across all those different complex chemical backbones. That makes perfect sense is like a universal adapter. Yeah. Here's where it gets really interesting though.
9:27Let's look at the actual data because theoretical elegance is one thing, but what happened when they put this into living systems? They didn't just test this in standard mice, right? No, they used a highly specialized model called the Hu 52 mouse.
9:39Who stands for humanized? Humanized mice. Yeah, the researchers essentially replaced a large segment of the mouse's genome with the human sequence for the DMD gene. Furthermore, the Delta 52 means Exon 52 is deleted.
9:52So they created a mouse that perfectly mimics a common human mutation causing severe muscular dystrophy. And because it has human genetic sequences, they can test the exact drug designed for human patients.
10:03That's right. They compared their new decoy enhanced ASO, which they called 000 A, LHC. Catchy name. Yeah, with L8Cs denoting that tiny 8 nucleotide lure. And they compared it against the traditional decoyless version modeled on a Teplarsen, which they called MOEE Tep.
10:21They administered the drugs and measured how effectively the target Exxon was skipped. When you look at the data, the leap in efficiency is staggering. The researchers found that just 3 milligrams per kilogram of the decoy enhanced drug achieve the exact same level of X on skipping as, wait for it.
10:39100 milligrams per kilogram of the older decoyless version. Yeah, that represents a roughly 30 fold increase in potence. In the world of pharmacology, you might spend a decade trying to achieve a 2 or threefold improvement.
10:53A 30 fold increase changes the entire landscape of treatment. It means you could potentially administer a tiny fraction of the current dose to get the same clinical effect, which minimizes side effects.
11:03Or you could use the standard dose and achieve a level of therapeutic rescue we have never seen before. And it wasn't just a molecular trick. We aren't just looking at RNA bands on a laboratory gel here.
11:13This translated into actual physical phenotypic rescue for these mice, right? Absolutely. They restored the dystrophine protein in both the skeletal muscle and the historically difficult to treat heart muscle.
11:24The functional rescue was profound. The mice treated with the 5D ASO went through physical evaluations, and they showed significantly improved grip strength across all 4 limbs compared to the untreated mice.
11:36We can actually quantify that muscle health internally too. They measured serum creatine kinase, or CK. If you are unfamiliar with CK, It is an enzyme found inside healthy muscle cells. When muscle fibers are damaged or rupture, which happens constantly in muscular dystrophy, that CK leaks out into the bloodstream.
11:55So high CK in the blood is a classic distress signal for muscle degeneration. And in the untreated mice, the CK levels were catastrophic. They were averaging 6715 units per liter. And when they treated them with the highest dose of the new 5D ASO?
12:10The levels plummeted down to just 1041 units per liter. Wow. That objective biochemical marker confirms that the muscle fibers are no longer degrading at that rapid rate. The dystrophine shock absorbers are back online and protecting the cells.
12:23I have to play devil's advocate here though. A mouse metabolism is incredibly fast, and their biology is quite different from ours. We've cured mice of countless diseases over the decades without it translating to humans.
12:36Does this decoy mechanism actually hold up in something closer to us? Mice are great, but does this work in a primate? The researchers progress their testing to cinemulgus monkeys. Oh, macaques. Yes. This is a critical translational step because these non-human primates shared the exact same genetic sequence for human Exxon 51.
12:55It is a one-to-one biological test run for the drugs targeting mechanism. And how did the movies fare? Delivery to a large primate's muscle tissue is notoriously difficult. They administered the lead 5DASO biweekly via intravenous infusion, and the data held up.
13:11They observed marked dos dependent Exxon skipping in both skeletal tissues, specifically the diaphragm and quadriceps, and crucially they saw significant skipping in the heart tissue. Oh, that fantastic.
13:21It demonstrated that the decoy mechanism scales effectively into large primates. So what does this all mean? If we are throwing 1000s of these tiny, highly effective decoys into a primate cells, Couldn't that accidentally mess up the splicing of 1000s of other healthy genes?
13:36If I hijacked the U1 scouts to focus on this one specific mutation? won't other genes get accidentally ignored or cut short? The spicy sum has to edit the rest of the genome properly to keep the cell alive.
13:48What's fascinating here is that the cellular biology naturally buffers this risk. U1 SNRMP is incredibly abundant in cells. Abundant enough to spare. Exactly. The researchers conducted exhaustive off target analyses, proving there is a safe concentration window.
14:04At effective therapeutic doses, the 5D ASO skipped the target DMD exon without causing global splicing defects, and they specifically checked to make sure it wasn't triggering premature cleavage and polyad annihilation or PCPA.
14:16PCPA. What is that? When a gene is transcribed, U1 acts as a shield to stop the RNA transcript from being chopped up before the whole gene is read. If you one is missing, those transcripts get cut prematurely.
14:27But the decoys didn't trigger this in other genes, like MT or STK 17 A, which are highly sensitive to U1 depletion. So the drug hits the target without causing friendly fire. Right. Furthermore, your analysis and blood tests in the monkey trial should a highly favorable safety profile.
14:45The monkeys tolerated it well. If we look at the broader implications, This isn't just about DMD, is it? No, the researchers prove this method works on multiple other genes. They tested it on SMN1 and SMN2 for spinal muscular atrophy, APP for Alzheimer's, and PKM for cancer.
15:02It worked across the board. That is incredible. But we still have that overarching delivery hurdle, right? Getting it through the tough exterior of a muscle cell in a human patient. Delivery remains the grand challenge.
15:14In the future, combining these 5D ASOs with targeted delivery systems like antibody oligonuclear tide conjugates, or AOCs, could push their efficacy even higher. By using an antibody like a homing missile to pull the drug inside the cell.
15:29Let's distill all this down to our core takeaways. By appending a tiny 8 nucleotide decoy tail to anti-sense oligonucleotides. Researchers can safely and intentionally misdirect the cell's splicing machinery.
15:43This simple structural modification yields up to a 30 fold increase in eggs on skipping potency in Vivo, offering a powerful new platform for treating genetic diseases like Duchenne muscular dystrophy.
15:55It really is a massive step forward. What does this mean for the future of genetic medicine? If a simple 8 letter decoy can transform a marginal treatment into a highly potent therapy. It's a question that is going to drive a lot of research in the coming years.
16:08This episode was based on an open access article under the CCBY 4.0 license, you can find a direct link to the paper and the license in our episode description. If you enjoy this, follow or subscribe in your podcast app and leave a five-star rating.
16:21If you'd like to support our work, use the donation link in the description. Now stay with us for an original track created especially for this episode and inspired by the article you've just heard about.
16:30Thanks for listening and join us next time as we explore more science, based by base.
